Perspectives on the use and risk of adverse events associated with cytokine-storm targeting antibodies and challenges associated with development of novel monoclonal antibodies for the treatment of COVID-19 clinical cases

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of the novel coronavirus disease 2019 (COVID-19) pandemic that lacks globally accessible effective antivirals or extensively available vaccines. Numerous clinical trials are exploring the applicability of repurpo...

Descripción completa

Detalles Bibliográficos
Autores principales: Johnson, Aishwarya Mary, Barigye, Robert, Saminathan, Hariharan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8127167/
https://www.ncbi.nlm.nih.gov/pubmed/33974497
http://dx.doi.org/10.1080/21645515.2021.1908060

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8127167/
https://www.ncbi.nlm.nih.gov/pubmed/33974497
http://dx.doi.org/10.1080/21645515.2021.1908060

Ejemplares similares